18F-FDG Positron Emission Tomography in Patients with Concomitant Malignancy and Tuberculoma.
- Author:
Jung Cheol LEE
1
;
Jin Sook RYU
;
I Nae PARK
;
Chang Min CHOI
;
Yeon Mok OH
;
Sang Do LEE
;
Woo Sung KIM
;
Dong Soon KIM
;
Tae Sun SHIM
Author Information
- Publication Type:Original Article
- Keywords: Positron-Emission Tomography; Neoplasms; Tuberculoma
- MeSH: Colon; Electrons; Female; Fluorodeoxyglucose F18; Humans; Liver; Lung; Lymph Nodes; Male; Ovary; Positron-Emission Tomography; Retrospective Studies; Stomach; Tuberculoma; Tuberculosis
- From:Tuberculosis and Respiratory Diseases 2010;68(1):1-5
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: To analyze the result of 18F-FDG positron emission tomography (PET) in patients with a concomitant malignancy and tuberculoma in a tuberculosis (TB)-endemic area. METHODS: Twelve patients with a concomitant malignancy and tuberculoma, who underwent whole-body 18F-FDG PET, were evaluated retrospectively. The maximal standardized uptake values (SUVmax) of the malignancy and tuberculoma were compared. In 6 patients, 18F-FDG PET was repeated during the anti-TB treatment and the changes in SUVmax were analyzed. RESULTS: Of the 12 patients, 10 were male. The mean age was 67.2+/-7.9 years. Tuberculomas were located in the lung (n=10) and lymph nodes (n=2), and tumors were located in the lung (n=6), colon (n=3), stomach (n=1), ovary (n=1) and liver (n=1). Although the mean SUVmax of malignant lesions was higher than that of tuberculomas (5.2+/-3.2 vs 3.5+/-2.0), the difference was not significant. In 4 patients, the SUVmax was higher in the tuberculoma than the tumor. After anti-TB treatment in 6 patients, the mean SUVmax of the tuberculomas decreased significantly, from 3.5+/-2.0 to 1.6+/-0.9 (p=0.028). CONCLUSION: In patients with a concomitant malignancy and tuberculoma, SUVmax alone could not differentiate between them. However, 18F-FDG PET may be useful in monitoring the response to anti-TB treatment.
